Abstract
Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances.
Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.
Keywords: NSCLC, target agents, therapy, cost, chemotherapy, metastases, prognoses.
Current Cancer Drug Targets
Title:Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review
Volume: 18 Issue: 5
Author(s): Alessandra Bearz*, Massimiliano Berretta and Umberto Tirelli
Affiliation:
- Department of Medical Oncology, National Cancer Institute, Aviano (PN),Italy
Keywords: NSCLC, target agents, therapy, cost, chemotherapy, metastases, prognoses.
Abstract: Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances.
Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.
Export Options
About this article
Cite this article as:
Bearz Alessandra*, Berretta Massimiliano and Tirelli Umberto, Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170206112408
DOI https://dx.doi.org/10.2174/1568009617666170206112408 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Current Drug Targets Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine A Comprehensive Review on Pharmacological Properties of Abrus precatorius L.
The Natural Products Journal A New “Era” for the α7-nAChR
Current Drug Targets Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Reduced-Intensity Transplantation in the Treatment of Haematological Malignancies: Current Status and Future-Prospects
Current Stem Cell Research & Therapy Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Current Medicinal Chemistry Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models
Clinical Cancer Drugs The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Low Content of Protein S29 in Ribosomes of Human Lung Cancer Cell Line A549: Detected by Twodimensional Electrophoresis
Protein & Peptide Letters Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance
Current Medicinal Chemistry Diagnostic Value of MiR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma
Current Molecular Medicine Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Prevention/ Therapy
Current Molecular Pharmacology